Morgan Stanley Rates Vir Biotechnology (VIR) buy
Morgan Stanley reaffirms its buy rating on VIR Biotechnology, setting a target price of $27.00, a 217.27% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Morgan Stanley rated Vir Biotechnology, Inc. ($VIR) "buy" with a $27 price target on June 11, 2026.
Since the rating, $VIR is up 7.5% after 1 week, up 14.1% after 1 month and up 16.9% to date (from the $8.52 close on Jun 11, 2026).
VIR
Vir Biotechnology, Inc.
Key Points
- Morgan Stanley reiterated its buy rating on VIR Biotechnology (VIR) with a target price of $27.00, while the stock recently traded at $8.51.
- Morgan Stanley's $27 price target implies 217.27% upside from Vir Biotechnology, Inc.'s ($VIR) current $8.51 share price.
- The company has seen impressive year-over-year revenue growth of nearly 196% to $303.2 million, despite posting a negative EPS of $1.77.
- VIR Biotechnology currently has a consensus recommendation of strong buy from nine analysts, with a mean target price of $20.78.
Get $VIR trade alerts by text
We text you when insiders, Congress or big funds trade $VIR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Vir Biotechnology, Inc. alert may contain errors. Disclosures
Morgan Stanley Reiterates Buy Rating
On June 11, 2026, Morgan Stanley reiterated its buy rating on VIR Biotechnology, Inc. (VIR) with a target price of $27.00. The stock was trading at $8.51 at the time of the assessment. This price point represents a significant potential upside based on the firm's optimistic outlook for the company's future.
Why Morgan Stanley is Bullish
Morgan Stanley's decision to maintain its buy rating comes amid strong revenue growth reported by VIR. The company achieved revenue of $303.2 million, reflecting a remarkable year-over-year revenue growth of approximately 195.8%. Although the company has a negative earnings per share (EPS) of $1.77, the solid revenue figures suggest a strong market position and growth potential in the biopharmaceutical field.
Analysts Set New Price Targets
Other analysts also support a positive view on VIR. For instance, on October 7, 2026, HC Wainwright & Co. maintained a Buy rating on the stock, raising their target price from $20.00 to $22.00. This consensus indicates that analysts see considerable growth potential for VIR despite its current challenges. The average target price among analysts now sits at $20.78, with a strong buy consensus from nine analysts covering the stock.
Stock Price Context
VIR's stock price of $8.51 is notably lower than its 52-week high of $11.94, indicating it might be undervalued at this price point. The stock is trading below its 200-day moving average of approximately $8.83, which could suggest a potential for recovery depending on market conditions and company performance.
$VIR price target
Vir Biotechnology, Inc. daily closes and this analyst's $27 target. Not advice.
What VIR Does
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. It focuses on discovering and developing therapeutic products aimed at treating and preventing serious infectious diseases. With a robust pipeline that includes investigational therapies for a range of conditions, VIR is well-positioned to capitalize on emerging healthcare needs.
What’s Next for VIR
Investors will be watching closely for the next earnings report scheduled for November 4, 2026. This upcoming report will provide further insights into the company's financial health and market position. It’s worth noting that the recent ratings from analysts indicate a strong belief in the company’s growth prospects, making it a stock to keep an eye on as developments unfold. Morgan Stanley’s reaffirmation of a buy rating highlights their confidence in VIR's potential to deliver value in the future.
Related Filing Alerts
Source: Morgan Stanley's rating change on $VIR (Jun 11, 2026). Written by software, not financial advice. How we make alerts